Method for detection of basic peptide and reagent for detection of basic peptide

Abstract

The present invention provides a method for detection of a basic peptide by mixing a sample suspected to contain the basic peptide and a reagent containing denatured albumin and detecting turbidness due to a complex of the basic peptide and denatured albumin.

1 - 10 . (canceled) 
     
     
         11 . A method for diagnosing a disease comprising:
 obtaining a sample from a biological specimen suspected of having a disease, wherein said disease is identifiable by detecting a basic peptide;   mixing the sample and a reagent comprising a heat-denatured albumin;   forming a complex comprising the basic peptide and the heat-denatured albumin;   obtaining optical information by irradiating the mixed sample and reagent with light;   detecting the basic peptide using said optical information.   
     
     
         12 . The method of  claim 11 , wherein the basic peptide is one or more of a adrenocorticotrophic hormone (ACTH), a brain natriuretic peptide (BNP), a atrial natriuretic peptide (ANP), a fibrinogen α, a ghrelin, a inter-α-trypsin inhibitor heavy chain subunit 4 (ITIH4), a prothrombin, kininogen, a proto-oncogene protein L-myc-1, a transcription factor SOX-3 or a α2-HS-glycoprotein. 
     
     
         13 . The method according to  claim 11 , wherein the basic peptide is a ACTH, and the disease is adrenal tumor, hyperadrenocorticism, panhypopituitarism or depression. 
     
     
         14 . The method according to  claim 11 , wherein the basic peptide is a BNP and the disease is heart failure. 
     
     
         15 . The method according to  claim 11 , wherein the basic peptide is a ANP and the disease is heart failure, renal failure or primary aldosteronism. 
     
     
         16 . The method according to  claim 11 , wherein the optical information is an optical density. 
     
     
         17 . The method according to  claim 16 , wherein the optical density is obtained from one or more of a refractive index, a reflected light intensity, a diffracted light intensity, an absorbance, a scattered light intensity, a fluorescence intensity, a phosphorescence intensity, a polarization state or an optical rotatory. 
     
     
         18 . A method for identifying a disease within a biological specimen comprising:
 obtaining a sample from the biological specimen suspected of being diseased, wherein said disease is identifiable by detecting a basic peptide;   mixing the sample and a reagent comprising a heat-denatured albumin;   forming a complex comprising the basic peptide and the heat-denatured albumin;   obtaining optical information by irradiating the mixed sample and reagent with light;   detecting the basic peptide using said optical information; and   identifying the disease.   
     
     
         19 . A method for preparing a complex comprising a basic peptide and a heat-denatured albumin wherein said basic peptide is indicative of disease, comprising:
 obtaining a sample from a biological specimen suspected of having a disease, wherein said disease is identifiable by detecting a basic peptide;   mixing the sample and a reagent comprising a heat-denatured albumin;   forming a complex comprising the basic peptide and the heat-denatured albumin;   obtaining optical information by irradiating the mixed sample and reagent with light;   detecting the basic peptide using said optical information.   
     
     
         20 . The method of  claim 18 , wherein:
 (a) the basic peptide is a ACTH, and the disease is adrenal tumor, hyperadrenocorticism, panhypopituitarism or depression, or   (b) the basic peptide is a BNP and the disease is heart failure, or   (c) the basic peptide is a ANP and the disease is heart failure, renal failure or primary aldosteronism.   
     
     
         21 . The method of  claim 18 , wherein the optical information is an optical density. 
     
     
         22 . The method according to  claim 21 , wherein the optical density is obtained from one or more of a refractive index, a reflected light intensity, a diffracted light intensity, an absorbance, a scattered light intensity, a fluorescence intensity, a phosphorescence intensity, a polarization state or an optical rotatory. 
     
     
         23 . The method of  claim 19 , wherein the optical information is an optical density. 
     
     
         24 . The method according to  claim 23 , wherein the optical density is obtained from one or more of a refractive index, a reflected light intensity, a diffracted light intensity, an absorbance, a scattered light intensity, a fluorescence intensity, a phosphorescence intensity, a polarization state or an optical rotatory. 
     
     
         25 . The method of  claim 18 , wherein the basic peptide is one or more of a adrenocorticotrophic hormone (ACTH), a brain natriuretic peptide (BNP), a atrial natriuretic peptide (ANP), a fibrinogen α, a ghrelin, a inter-α-trypsin inhibitor heavy chain subunit 4 (ITIH4), a prothrombin, kininogen, a proto-oncogene protein L-myc-1, a transcription factor SOX-3 or a α2-HS-glycoprotein. 
     
     
         26 . The method according to  claim 18 , wherein the basic peptide is a ACTH, and the disease is adrenal tumor, hyperadrenocorticism, panhypopituitarism or depression. 
     
     
         27 . The method of  claim 19 , wherein the basic peptide is one or more of a adrenocorticotrophic hormone (ACTH), a brain natriuretic peptide (BNP), a atrial natriuretic peptide (ANP), a fibrinogen α, a ghrelin, a inter-α-trypsin inhibitor heavy chain subunit 4 (ITIH4), a prothrombin, kininogen, a proto-oncogene protein L-myc-1, a transcription factor SOX-3 or a α2-HS-glycoprotein. 
     
     
         28 . The method according to  claim 19 , wherein the basic peptide is a ACTH, and the disease is adrenal tumor, hyperadrenocorticism, panhypopituitarism or depression. 
     
     
         29 . The method according to  claim 18 , wherein the basic peptide is a BNP and the disease is heart failure, or
 wherein the basic peptide is a ANP and the disease is heart failure, renal failure or primary aldosteronism.   
     
     
         30 . The method according to  claim 19 , wherein the basic peptide is a BNP and the disease is heart failure, or
 wherein the basic peptide is a ANP and the disease is heart failure, renal failure or primary aldosteronism.